A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin experienced only "mild to moderate" ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...